ImmunoGen Reports Recent Progress and 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/10/2026
- Wall Street ends down as expectations of Hormuz deal fade
- JPMorgan lifts S&P 500 target to 8,000 on strong earnings
- Nvidia and Wall Street giants plan $500B AI funding deal, FT reports
- Jefferies cuts Apple rating as higher-priced iPhone roadmap looks difficult
- Oil climbs 5% as Iran, US both demand compensation and Hormuz hopes fade
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
Immunogen (IMGN) Tops Q4 EPS by 26c, Offers Q1 Guidance
February 12, 2021 6:32 AM ESTImmunogen (NASDAQ: IMGN) reported Q4 EPS of $0.16, $0.26 better than the analyst estimate of ($0.10). Revenue for the quarter came in at $85.8 million versus the consensus estimate of $37.09 million.
GUIDANCE:
Immunogen sees Q1 2021 revenue of $65-75 million, versus the consensus of $53.1... More
